Description

Janumet is a combination medication used to treat type 2 diabetes in adults. It contains the active ingredients sitagliptin and metformin:

• Sitagliptin is a DPP-4 inhibitor that helps increase insulin production and decrease the amount of sugar produced by the liver.
• Metformin is a biguanide that improves the body’s sensitivity to insulin and reduces the amount of glucose produced by the liver.

The key points about Janumet 50/1000 mg 56’ct tablet are:

• It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
• The recommended starting dose is sitagliptin 50 mg twice daily plus the patient’s current metformin dose.
• It is contraindicated in patients with severe renal impairment (GFR < 30 mL/min), acute metabolic acidosis, and other conditions that can increase the risk of lactic acidosis.
• Common side effects include diarrhea, nausea, and upper respiratory tract infection.
• Janumet should be taken twice daily with meals to reduce gastrointestinal side effects from the metformin component.
  

  Combination of DPP-4 inhibitor and biguanide

  Janumet is a unique combination of two different classes of diabetes medications – sitagliptin (a DPP-4 inhibitor) and metformin (a biguanide). This combination targets multiple pathways to improve glycemic control.

  Convenient once-daily dosing

  Unlike some other combination diabetes medications, Janumet is dosed twice daily with meals. This can be more convenient for patients compared to taking multiple pills separately.

  Helps reduce HbA1c levels

  Clinical studies have shown that Janumet can significantly reduce HbA1c levels compared to either sitagliptin or metformin alone. It helps many patients achieve their target blood sugar goals.

  Potential for weight neutrality

  While metformin alone can cause weight loss, the addition of sitagliptin in Janumet appears to be weight neutral. This can be beneficial for patients concerned about potential weight gain with diabetes medications.

  Renal dosing adjustments

  For patients with renal impairment, the dose of Janumet needs to be adjusted based on the estimated glomerular filtration rate (eGFR). This allows for safer use in patients with kidney disease.

  Extensive clinical experience

  Sitagliptin, one of the active ingredients in Janumet, has been used clinically for over 15 years. This provides a wealth of real-world evidence on its safety and efficacy profile.

  Key Benefits:

  • Helps control blood sugar levels in adults with type 2 diabetes
  • Targets multiple mechanisms to improve glycemic control:
    • Increases insulin production
    • Improves insulin sensitivity
    • Reduces glucose production by the liver
  • Can be used alone or in combination with other diabetes medications
  • Convenient twice-daily dosing with meals

  Key Ingredients:

  • Sitagliptin (50 mg) – a DPP-4 inhibitor that helps increase insulin production and decrease liver glucose output
  • Metformin (1000 mg) – a biguanide that improves insulin sensitivity and reduces glucose production by the liver

  The combination of these two active ingredients in Janumet provides a complementary approach to managing type 2 diabetes by targeting multiple pathways to improve glycemic control.                                                                                                                              The key mechanism of action of Janumet 50/1000 mg 56’ct tablet is:

  Sitagliptin (DPP-4 inhibitor)

  • Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that slows the inactivation of incretin hormones like GLP-1 and GIP.
  • This increases and prolongs the action of these hormones, which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner.

  Metformin (biguanide)

  • Metformin improves glucose tolerance by:
    • Decreasing hepatic glucose production
    • Decreasing intestinal absorption of glucose
    • Improving insulin sensitivity by increasing peripheral glucose uptake and utilization
  • Unlike sulfonylureas, metformin does not cause insulin release or hypoglycemia when glucose levels are normal or low.

  The combination of sitagliptin and metformin in Janumet targets multiple pathways to improve glycemic control in patients with type 2 diabetes. Sitagliptin enhances incretin effects while metformin reduces glucose production and improves insulin sensitivity.

  

  Sitagliptin

  Anti-diabetic Medication for Type 2 Diabetes

  More

  Trade Names

  Januvia, Zituvio, others

  Common Side Effects

  Headaches, leg swelling, upper respiratory tract infections

  Serious Side Effects

  Angioedema, low blood sugar, kidney problems, pancreatitis, joint pain

  The key chemical structure of sitagliptin, one of the active ingredients in Janumet 50/1000 mg 56’ct tablet, is:

  c1c(c(cc(c1F)F)F)C[C@H](CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)N


  This SMILES notation represents the 2D structure of sitagliptin, which has the molecular formula C16H15F6N5O.Some key structural features of sitagliptin:

  • Contains a trifluoromethyl-substituted triazolopyrazine ring system
  • Has a 2,4,5-trifluorophenyl group attached to the side chain
  • Includes a carbonyl group and an amino group in the side chain
  • Has one defined stereocenter with the (3R) configuration

  The phosphate salt form of sitagliptin, sitagliptin phosphate monohydrate, has the molecular formula C16H20F6N5O6P. This salt is more water soluble compared to the free base form of sitagliptin.

  Dosage

  • The recommended starting dose is sitagliptin 50 mg twice daily plus the patient’s current metformin dose.
  • The maximum daily dose of Janumet is 100 mg sitagliptin and the patient’s current metformin dose.
  • Janumet should be taken twice daily with meals to reduce gastrointestinal side effects from metformin.
  • Dose adjustments may be needed for patients with renal impairment.

  Storage

  • Janumet should be stored at 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F).
  • It should be kept in the original package to protect from moisture.

  Reviews

  The search results do not contain any specific reviews or patient feedback about Janumet 50/1000 mg 56’ct tablet. The information focuses more on the clinical and regulatory details of the medication.